Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
immunosuppressant |
| gptkbp:administeredBy |
subcutaneous injection
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L04AC03
|
| gptkbp:brand |
Zinbryta
|
| gptkbp:CASNumber |
152923-56-3
|
| gptkbp:developedBy |
gptkb:Biogen
gptkb:AbbVie |
| gptkbp:hasMolecularFormula |
C6428H9954N1714O2016S46
|
| https://www.w3.org/2000/01/rdf-schema#label |
daclizumab
|
| gptkbp:legalStatus |
withdrawn
|
| gptkbp:mechanismOfAction |
binds to IL-2 receptor alpha chain
|
| gptkbp:retired |
serious inflammatory brain disorders
|
| gptkbp:routeOfAdministration |
subcutaneous
|
| gptkbp:sideEffect |
liver injury
immune-mediated disorders |
| gptkbp:target |
gptkb:CD25
|
| gptkbp:UNII |
QGX9K1F1WZ
|
| gptkbp:usedFor |
multiple sclerosis
prevention of organ transplant rejection |
| gptkbp:withdrawn |
2018
|
| gptkbp:bfsParent |
gptkb:CD25
|
| gptkbp:bfsLayer |
6
|